查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1513682

全球宠物过敏治疗市场：产业分析、规模、占有率、成长、趋势、预测，2024-2031

Pet Allergy Treatment Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2031
出版日期: | 出版商: Persistence Market Research | 英文 156 Pages | 商品交期: 2-5个工作天内

价格
简介目录

本报告发布了全球宠物过敏治疗市场的综合报告。详细分析市场驱动因素、趋势、机会和课题等关键市场动态，以提供对市场前景的深入见解。

关键见解

  • 宠物过敏治疗市场规模（2024 年）：26.712 亿美元
  • 预测市场金额（2031 年）：3,930,760,000 美元
  • 全球市场成长率（2024-2031 年复合年增长率）：5.7%

宠物过敏治疗市场 - 研究范围

宠物过敏是全世界宠物及其主人的主要健康问题。宠物过敏治疗市场包括多种治疗方案，旨在控制猫和狗等宠物引起的过敏反应。这些治疗包括药物治疗、免疫疗法、过敏原避免策略和新的生物疗法。该市场服务于兽医诊所、医院、宠物护理中心和家庭护理设施，满足宠物主人对有效过敏管理解决方案不断增长的需求。

推动市场成长的因素：

全球宠物过敏治疗市场受到多种因素的推动，包括宠物拥有量的增加、对宠物过敏的认识不断提高以及兽医学的进步。宠物主人和宠物中过敏性疾病的流行增加了对有效治疗方案的需求。诊断工具和治疗方法的技术创新提高了诊断准确性和治疗效果，进一步推动市场成长。此外，宠物保险覆盖范围的扩大和宠物医疗基础设施的投资也有助于市场扩张。

市场限制因素：

虽然宠物过敏治疗市场有望实现成长，但它面临着监管合规性、治疗结果的可变性以及主人对处方治疗的依从性等方面的课题。兽药和生物製品的监管框架给製造商和医疗保健提供者带来了合规负担，影响了市场动态和业务策略。此外，一些地区先进治疗的高成本和有限的报销范围阻碍了市场渗透，特别是在新兴市场。

市场机会：

由于人口趋势、宠物日益人性化以及消费者对宠物保健产品和服务的偏好不断变化，宠物过敏治疗市场呈现出巨大的成长机会。远距医疗和数位健康解决方案的整合促进了远端咨询并改善了业主获得兽医护理的机会。此外，兽药公司、宠物食品製造商和过敏专家之间的合作将促进治疗方案和过敏原管理策略的创新。为了利用新的市场机会，对研究和开发的策略性投资以及针对宠物主人和兽医专业人员的教育举措至关重要。

本报告涵盖的主要问题

  • 推动全球宠物过敏治疗市场成长的因素有哪些？
  • 哪些治疗和诊断工具越来越受到宠物主人和兽医专业人士的欢迎？
  • 科技进步如何改变宠物过敏治疗市场的竞争格局？
  • 谁是宠物过敏治疗市场的主要参与者？
  • 全球宠物过敏治疗市场的新趋势和未来前景如何？

目录

第 1 章执行摘要

第二章市场概述

  • 市场范围/分类
  • 市场定义/范围/限制
  • 包含和排除

第三章主要市场趋势

  • 影响市场的主要趋势
  • 产品创新/发展趋势

第 4 章增值见解

  • 产品采用率分析
  • 依品牌划分的产品 USP/功能分析
  • 各国的监理状况
  • 近期产品核准/发布
  • 疾病流行病学
  • 波特的分析
  • 杵分析
  • 价值链分析
  • 未满足的需求

第五章市场背景

  • 宏观经济因素
  • 预测因子 - 相关性和影响
  • 市场动态

第六章全球市场需求（金额或规模，百万美元）分析

  • 2019-2023 年过去的市值（百万美元）分析
  • 2024-2031 年当前及未来市场规模（百万美元）预测
    • 年成长趋势分析
    • 绝对美元机会分析
  • 收入机会情境 - 可能/保守/乐观

第 7 章全球市场分析：依药物类别

  • 简介/主要发现
  • 2019-2023 年历史市场规模（百万美元）分析（依药物类别）
  • 2024-2031 年当前和未来市场规模（百万美元）分析和预测（依药物类别）
    • 抗组织胺药
    • 皮质类固醇
    • 免疫治疗
    • 抗生素
  • 市场吸引力分析：依药物类别

第 8 章全球市场分析：依迹象

  • 简介/主要发现
  • 2019-2023 年历史市场规模（百万美元）分析（依指标）
  • 2024-2031 年当前和未来市场规模（百万美元）分析和预测（依指标）
    • 过敏性皮肤炎
    • 食物过敏
    • 跳蚤/螨过敏
    • 接触过敏
  • 市场吸引力分析：依指标分类

第 9 章全球市场分析：依宠物类型

  • 简介/主要发现
  • 2019-2023 年过去的市场规模（百万美元）分析（依宠物类型）
  • 2024-2031 年当前和未来市场规模（百万美元）分析和预测（依宠物类型）
    • 狗
    • 猫
    • 囓齿动物/兔子
  • 市场吸引力分析：依宠物类型

第 10 章全球市场分析：依管理途径

  • 简介/主要发现
  • 2019-2023 年依管理途径划分的历史市场规模（百万美元）分析
  • 2024-2031 年当前和未来市场规模（百万美元）分析和预测（依管理方式）
    • 口服製剂
    • 注射
    • 本地
  • 市场吸引力分析：依给药途径

第 11 章世界市场分析：依通路

  • 简介/主要发现
  • 2019-2023 年过去的市场规模（百万美元）分析（依分销管道）
  • 2024-2031 年当前和未来市场规模（百万美元）分析和预测（依分销管道）
    • 动物医院
    • 零售药局
    • 网路药局
    • 其他
  • 市场吸引力分析：依分销管道

第 12 章世界市场分析：依地区

  • 简介/主要发现
  • 2019-2023 年依地区划分的过往市场规模（百万美元）分析
  • 2024-2031 年当前和未来市场规模（百万美元）分析和预测（依地区）
    • 北美
    • 拉丁美洲
    • 欧洲
    • 南亚
    • 东亚
    • 大洋洲
    • 中东/非洲
  • 市场吸引力分析：依地区划分

第十三章北美市场分析

第 14 章拉丁美洲市场分析

第 15 章欧洲市场分析

第16章东亚市场分析

第十七章南亚市场分析

第18章大洋洲市场分析

第十九章中东/非洲市场分析

第20章市场结构分析

  • 市场分析：依公司层级
  • 主要企业市占率分析（%）
  • 市场现况分析

第21章竞争分析

  • 竞争对手仪表板
  • 主要发展分析
  • 主要参与者的品牌和推广策略
  • 衝突详情
    • Zoetis Animal Healthcare
    • Merck and Co.Inc.（US）
    • Boehringer Ingelheim GmbH
    • Elanco Animal Health Incorporated
    • Bayer AG
    • Vetoquinol SA
    • Dechra Pharmaceuticals PLC
    • Virbac SA
    • IDEXX Laboratories, Inc.
    • Ceva Sante Animale
    • Kindred Biosciences, Inc.
    • Phirbo Animal Health
    • Norbrook Laboratories Limited
    • Vetiquinol SA
    • Neogen Corporation
    • PetIQ, Inc.
    • Huvepharma AD
    • Chanelle Pharma Group Limited
    • Kepro
    • Biogenesis Bago

第 22 章使用的假设与缩写

第23章研究方法

简介目录
Product Code: PMRREP28603

Persistence Market Research has recently released a comprehensive report on the global Pet Allergy Treatment Market. The report provides an in-depth analysis of key market dynamics, including drivers, trends, opportunities, and challenges, offering detailed insights into the market landscape.

Key Insights:

  • Pet Allergy Treatment Market Size (2024E): USD 2,671.20 million
  • Projected Market Value (2031F): USD 3,930.76 million
  • Global Market Growth Rate (CAGR 2024 to 2031):5.7%

Pet Allergy Treatment Market - Report Scope:

Pet allergies represent a significant health concern for both pets and their owners globally. The market for pet allergy treatment encompasses a range of therapeutic options aimed at managing allergic reactions caused by pets, such as cats and dogs. These treatments include medications, immunotherapy, allergen avoidance strategies, and emerging biologic therapies. The market caters to veterinary clinics, hospitals, pet care centers, and homecare settings, addressing a growing demand from pet owners seeking effective allergy management solutions.

Market Growth Drivers:

The global pet allergy treatment market is driven by several factors, including increasing pet ownership, rising awareness about pet allergies, and advancements in veterinary medicine. The growing prevalence of allergic conditions among pet owners and pets alike underscores the need for effective treatment options. Technological innovations in diagnostic tools and treatment modalities further enhance market growth, improving diagnostic accuracy and treatment efficacy. Moreover, the expanding pet insurance coverage and investments in pet healthcare infrastructure contribute to market expansion.

Market Restraints:

Despite promising growth prospects, the pet allergy treatment market faces challenges related to regulatory compliance, variability in treatment outcomes, and pet owner adherence to prescribed therapies. Regulatory frameworks governing veterinary pharmaceuticals and biologics impose compliance burdens on manufacturers and healthcare providers, influencing market dynamics and operational strategies. Additionally, the high cost of advanced treatments and limited reimbursement coverage in some regions hinder market penetration, particularly in emerging economies.

Market Opportunities:

The pet allergy treatment market presents significant growth opportunities driven by demographic trends, increasing pet humanization, and evolving consumer preferences for pet healthcare products and services. The integration of telemedicine and digital health solutions facilitates remote consultations and enhances pet owner access to veterinary care. Furthermore, collaborations between veterinary pharmaceutical companies, pet food manufacturers, and allergy specialists foster innovation in treatment protocols and allergen management strategies. Strategic investments in research and development, along with educational initiatives targeting pet owners and veterinary professionals, are essential to capitalize on emerging market opportunities.

Key Questions Answered in the Report:

  • What factors are driving the growth of the pet allergy treatment market globally?
  • Which treatment modalities and diagnostic tools are gaining traction among pet owners and veterinary professionals?
  • How are technological advancements reshaping the competitive landscape of the pet allergy treatment market?
  • Who are the key players contributing to the pet allergy treatment market, and what strategies are they employing to maintain market leadership?
  • What are the emerging trends and future prospects in the global pet allergy treatment market?

Competitive Intelligence and Business Strategy:

Leading players in the global pet allergy treatment market, including pharmaceutical companies, veterinary clinics, and biotechnology firms, focus on innovation, product differentiation, and strategic partnerships to gain a competitive edge. These companies invest in R&D to develop novel therapies, diagnostic tests, and allergen management solutions, catering to diverse pet owner preferences and clinical needs. Collaborations with pet healthcare providers, regulatory agencies, and pet insurance companies facilitate market access and promote technology adoption. Moreover, emphasis on evidence-based practice, veterinary education, and pet owner engagement enhances treatment outcomes and supports sustainable market growth in the evolving landscape of pet allergy management.

Key Companies Profiled:

  • Zoetis Animal Healthcare
  • Merck and Co Inc.
  • Boehringer Ingelheim GmbH
  • Elanco Animal Health Incorporated
  • Bayer AG
  • Vetoquinol S.A.
  • Dechra Pharmaceuticals PLC
  • Virbac SA
  • IDEXX Laboratories, Inc.
  • Ceva Sante Animale
  • Kindred Biosciences, Inc.
  • Phirbo Animal Health
  • Norbrook Laboratories Limited
  • Vetiquinol SA
  • Neogen Corporation
  • PetIQ, Inc.
  • Huvepharma AD

Key Segments of Pet Allergy Treatment Industry Research

By Drug Class:

  • Antihistamines
  • Corticosteroids
  • Immunotherapy
  • Antibiotics

By Indication:

  • Allergic Dermatitis
  • Food Allergy
  • Fleabite Allergy
  • Contact Allergy

By Pet Type:

  • Dogs
  • Cats
  • Rodents & Rabbits

By Route of Administration:

  • Oral
  • Injectable
  • Topical

By Distribution Channel:

  • Veterinary Hospitals
  • Retail Pharmacies
  • Online Pharmacies

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East and Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Market Outlook
  • 1.2. Demand-side Trends
  • 1.3. Supply-side Trends
  • 1.4. Analysis and Recommendations

2. Market Overview

  • 2.1. Market Coverage / Taxonomy
  • 2.2. Market Definition / Scope / Limitations
  • 2.3. Inclusions and Exclusions

3. Key Market Trends

  • 3.1. Key Trends Impacting the Market
  • 3.2. Product Innovation / Development Trends

4. Value Added Insights

  • 4.1. Product Adoption Analysis
  • 4.2. Product USPs/Features Analysis, By Brands
  • 4.3. Regulatory Landscape, By Country
  • 4.4. Recent Product Approval/Launches
  • 4.5. Disease Epidemiology
  • 4.6. Porter's Analysis
  • 4.7. PESTLE Analysis
  • 4.8. Value Chain Analysis
  • 4.9. Unmet Needs

5. Market Background

  • 5.1. Macro-Economic Factors
    • 5.1.1. Global Healthcare Expenditure Outlook
    • 5.1.2. Global Pharmaceutical Market Outlook
    • 5.1.3. Global Animal Healthcare Market Outlook
  • 5.2. Forecast Factors - Relevance & Impact
    • 5.2.1. Rising Rate of Pet Adoption
    • 5.2.2. Increase in Research and Development
    • 5.2.3. Strategic Collaborations among players
    • 5.2.4. Cost of Product
    • 5.2.5. Business Expansions
    • 5.2.6. Frequency of Product Approval
    • 5.2.7. Pet Care Insurance
  • 5.3. Market Dynamics
    • 5.3.1. Drivers
    • 5.3.2. Restraints
    • 5.3.3. Opportunity Analysis

6. Global Market Demand (in Value or Size in US$ Million) Analysis 2019-2023 and Forecast, 2024-2031

  • 6.1. Historical Market Value (US$ Million) Analysis, 2019-2023
  • 6.2. Current and Future Market Size (US$ Million) Projections, 2024-2031
    • 6.2.1. Y-o-Y Growth Trend Analysis
    • 6.2.2. Absolute $ Opportunity Analysis
  • 6.3. Revenue Opportunity Scenario- Likely/Conservative/Optimistic

7. Global Market Analysis 2019-2023 and Forecast 2024-2031, By Drug Class

  • 7.1. Introduction / Key Findings
  • 7.2. Historical Market Size (US$ Million) Analysis By Drug Class, 2019-2023
  • 7.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Drug Class, 2024-2031
    • 7.3.1. Antihistamines
    • 7.3.2. Corticosteroids
    • 7.3.3. Immunotherapy
    • 7.3.4. Antibiotics
  • 7.4. Market Attractiveness Analysis By Drug Class

8. Global Market Analysis 2019-2023 and Forecast 2024-2031, By Indication

  • 8.1. Introduction / Key Findings
  • 8.2. Historical Market Size (US$ Million) Analysis By Indication, 2019-2023
  • 8.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Indication, 2024-2031
    • 8.3.1. Allergic Dermatitis
    • 8.3.2. Food Allergy
    • 8.3.3. Fleabite Allergy
    • 8.3.4. Contact Allergy
  • 8.4. Market Attractiveness Analysis By Indication

9. Global Market Analysis 2019-2023 and Forecast 2024-2031, By Pet Type

  • 9.1. Introduction / Key Findings
  • 9.2. Historical Market Size (US$ Million) Analysis By Pet Type, 2019-2023
  • 9.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Pet Type, 2024-2031
    • 9.3.1. Dogs
    • 9.3.2. Cats
    • 9.3.3. Rodents and rabbits
  • 9.4. Market Attractiveness Analysis By Pet Type

10. Global Market Analysis 2019-2023 and Forecast 2024-2031, By Route of Administration

  • 10.1. Introduction / Key Findings
  • 10.2. Historical Market Size (US$ Million) Analysis By Route of Administration, 2019-2023
  • 10.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Route of Administration, 2024-2031
    • 10.3.1. Oral
    • 10.3.2. Injectable
    • 10.3.3. Topical
  • 10.4. Market Attractiveness Analysis By Route of Administration

11. Global Market Analysis 2019-2023 and Forecast 2024-2031, By Distribution Channel

  • 11.1. Introduction / Key Findings
  • 11.2. Historical Market Size (US$ Million) Analysis By Distribution Channel, 2019-2023
  • 11.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Distribution Channel, 2024-2031
    • 11.3.1. Veterinary Hospitals
    • 11.3.2. Retail Pharmacies
    • 11.3.3. Online Pharmacies
    • 11.3.4. Others
  • 11.4. Market Attractiveness Analysis By Distribution Channel

12. Global Market Analysis 2019-2023 and Forecast 2024-2031, by Region

  • 12.1. Introduction / Key Findings
  • 12.2. Historical Market Size (US$ Million) Analysis By Region, 2019-2023
  • 12.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Region, 2024-2031
    • 12.3.1. North America
    • 12.3.2. Latin America
    • 12.3.3. Europe
    • 12.3.4. South Asia
    • 12.3.5. East Asia
    • 12.3.6. Oceania
    • 12.3.7. Middle East and Africa
  • 12.4. Market Attractiveness Analysis By Region

13. North America Market Analysis 2019-2023 and Forecast 2024-2031

  • 13.1. Introduction / Key Findings
  • 13.2. Historical Market Size (US$ Million) Analysis, By Market Taxonomy, 2019-2023
  • 13.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2024-2031
    • 13.3.1. By Country
      • 13.3.1.1. United States
      • 13.3.1.2. Canada
    • 13.3.2. By Drug Class
    • 13.3.3. By Indication
    • 13.3.4. By Pet Type
    • 13.3.5. By Route of Administration
    • 13.3.6. By Distribution Channel
  • 13.4. Market Attractiveness Analysis By Region
    • 13.4.1. By Country
    • 13.4.2. By Drug Class
    • 13.4.3. By Indication
    • 13.4.4. By Pet Type
    • 13.4.5. By Route of Administration
    • 13.4.6. By Distribution Channel
  • 13.5. Market trends
  • 13.6. Key Market Participants - Intensity Mapping
  • 13.7. Drivers and Restraints - Impact Analysis
  • 13.8. Country Level Analysis & Forecast
    • 13.8.1. United States Market Analysis
      • 13.8.1.1. Introduction
      • 13.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.1.2.1. By Drug Class
        • 13.8.1.2.2. By Indication
        • 13.8.1.2.3. By Pet Type
        • 13.8.1.2.4. By Route of Administration
        • 13.8.1.2.5. By Distribution Channel
    • 13.8.2. Canada Market Analysis
      • 13.8.2.1. Introduction
      • 13.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.2.2.1. By Drug Class
        • 13.8.2.2.2. By Indication
        • 13.8.2.2.3. By Pet Type
        • 13.8.2.2.4. By Route of Administration
        • 13.8.2.2.5. By Distribution Channel

14. Latin America Market Analysis 2019-2023 and Forecast 2024-2031

  • 14.1. Introduction / Key Findings
  • 14.2. Historical Market Size (US$ Million) Analysis, By Market Taxonomy, 2019-2023
  • 14.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2024-2031
    • 14.3.1. By Country
      • 14.3.1.1. Brazil
      • 14.3.1.2. Mexico
      • 14.3.1.3. Argentina
      • 14.3.1.4. Rest of Latin America
    • 14.3.2. By Drug Class
    • 14.3.3. By Indication
    • 14.3.4. By Pet Type
    • 14.3.5. By Route of Administration
    • 14.3.6. By Distribution Channel
  • 14.4. Market Attractiveness Analysis By Region
    • 14.4.1. By Country
    • 14.4.2. By Drug Class
    • 14.4.3. By Indication
    • 14.4.4. By Pet Type
    • 14.4.5. By Route of Administration
    • 14.4.6. By Distribution Channel
  • 14.5. Market trends
  • 14.6. Key Market Participants - Intensity Mapping
  • 14.7. Drivers and Restraints - Impact Analysis
  • 14.8. Country Level Analysis & Forecast
    • 14.8.1. Brazil Market Analysis
      • 14.8.1.1. Introduction
      • 14.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.1.2.1. By Drug Class
        • 14.8.1.2.2. By Indication
        • 14.8.1.2.3. By Pet Type
        • 14.8.1.2.4. By Route of Administration
        • 14.8.1.2.5. By Distribution Channel
    • 14.8.2. Mexico Market Analysis
      • 14.8.2.1. Introduction
      • 14.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.2.2.1. By Drug Class
        • 14.8.2.2.2. By Indication
        • 14.8.2.2.3. By Pet Type
        • 14.8.2.2.4. By Route of Administration
        • 14.8.2.2.5. By Distribution Channel
    • 14.8.3. Argentina Market Analysis
      • 14.8.3.1. Introduction
      • 14.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.3.2.1. By Drug Class
        • 14.8.3.2.2. By Indication
        • 14.8.3.2.3. By Pet Type
        • 14.8.3.2.4. By Route of Administration
        • 14.8.3.2.5. By Distribution Channel

15. Europe Market Analysis 2019-2023 and Forecast 2024-2031

  • 15.1. Introduction / Key Findings
  • 15.2. Historical Market Size (US$ Million) Analysis, By Market Taxonomy, 2019-2023
  • 15.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2024-2031
    • 15.3.1. By Country
      • 15.3.1.1. Germany
      • 15.3.1.2. France
      • 15.3.1.3. Spain
      • 15.3.1.4. Russia
      • 15.3.1.5. Italy
      • 15.3.1.6. BENELUX
      • 15.3.1.7. United Kingdom
      • 15.3.1.8. Rest of Europe
    • 15.3.2. By Drug Class
    • 15.3.3. By Indication
    • 15.3.4. By Pet Type
    • 15.3.5. By Route of Administration
    • 15.3.6. By Distribution Channel
  • 15.4. Market Attractiveness Analysis By Region
    • 15.4.1. By Country
    • 15.4.2. By Drug Class
    • 15.4.3. By Indication
    • 15.4.4. By Pet Type
    • 15.4.5. By Route of Administration
    • 15.4.6. By Distribution Channel
  • 15.5. Market trends
  • 15.6. Key Market Participants - Intensity Mapping
  • 15.7. Drivers and Restraints - Impact Analysis
  • 15.8. Country Level Analysis & Forecast
    • 15.8.1. Germany Market Analysis
      • 15.8.1.1. Introduction
      • 15.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.1.2.1. By Drug Class
        • 15.8.1.2.2. By Indication
        • 15.8.1.2.3. By Pet Type
        • 15.8.1.2.4. By Route of Administration
        • 15.8.1.2.5. By Distribution Channel
    • 15.8.2. France Market Analysis
      • 15.8.2.1. Introduction
      • 15.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.2.2.1. By Drug Class
        • 15.8.2.2.2. By Indication
        • 15.8.2.2.3. By Pet Type
        • 15.8.2.2.4. By Route of Administration
        • 15.8.2.2.5. By Distribution Channel
    • 15.8.3. Spain Market Analysis
      • 15.8.3.1. Introduction
      • 15.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.3.2.1. By Drug Class
        • 15.8.3.2.2. By Indication
        • 15.8.3.2.3. By Pet Type
        • 15.8.3.2.4. By Route of Administration
        • 15.8.3.2.5. By Distribution Channel
    • 15.8.4. Russia Market Analysis
      • 15.8.4.1. Introduction
      • 15.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.4.2.1. By Drug Class
        • 15.8.4.2.2. By Indication
        • 15.8.4.2.3. By Pet Type
        • 15.8.4.2.4. By Route of Administration
        • 15.8.4.2.5. By Distribution Channel
    • 15.8.5. Italy Market Analysis
      • 15.8.5.1. Introduction
      • 15.8.5.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.5.2.1. By Drug Class
        • 15.8.5.2.2. By Indication
        • 15.8.5.2.3. By Pet Type
        • 15.8.5.2.4. By Route of Administration
        • 15.8.5.2.5. By Distribution Channel
    • 15.8.6. BENELUX Market Analysis
      • 15.8.6.1. Introduction
      • 15.8.6.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.6.2.1. By Drug Class
        • 15.8.6.2.2. By Indication
        • 15.8.6.2.3. By Pet Type
        • 15.8.6.2.4. By Route of Administration
        • 15.8.6.2.5. By Distribution Channel
    • 15.8.7. United Kingdom Market Analysis
      • 15.8.7.1. Introduction
      • 15.8.7.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.7.2.1. By Drug Class
        • 15.8.7.2.2. By Indication
        • 15.8.7.2.3. By Pet Type
        • 15.8.7.2.4. By Route of Administration
        • 15.8.7.2.5. By Distribution Channel

16. East Asia Market Analysis 2019-2023 and Forecast 2024-2031

  • 16.1. Introduction / Key Findings
  • 16.2. Historical Market Size (US$ Million) Analysis, By Market Taxonomy, 2019-2023
  • 16.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2024-2031
    • 16.3.1. By Country
      • 16.3.1.1. China
      • 16.3.1.2. Japan
      • 16.3.1.3. South Korea
    • 16.3.2. By Drug Class
    • 16.3.3. By Indication
    • 16.3.4. By Pet Type
    • 16.3.5. By Route of Administration
    • 16.3.6. By Distribution Channel
  • 16.4. Market Attractiveness Analysis By Region
    • 16.4.1. By Country
    • 16.4.2. By Drug Class
    • 16.4.3. By Indication
    • 16.4.4. By Pet Type
    • 16.4.5. By Route of Administration
    • 16.4.6. By Distribution Channel
  • 16.5. Market trends
  • 16.6. Key Market Participants - Intensity Mapping
  • 16.7. Drivers and Restraints - Impact Analysis
  • 16.8. Country Level Analysis & Forecast
    • 16.8.1. China Market Analysis
      • 16.8.1.1. Introduction
      • 16.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.1.2.1. By Drug Class
        • 16.8.1.2.2. By Indication
        • 16.8.1.2.3. By Pet Type
        • 16.8.1.2.4. By Route of Administration
        • 16.8.1.2.5. By Distribution Channel
    • 16.8.2. Japan Market Analysis
      • 16.8.2.1. Introduction
      • 16.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.2.2.1. By Drug Class
        • 16.8.2.2.2. By Indication
        • 16.8.2.2.3. By Pet Type
        • 16.8.2.2.4. By Route of Administration
        • 16.8.2.2.5. By Distribution Channel
    • 16.8.3. South Korea Market Analysis
      • 16.8.3.1. Introduction
      • 16.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.3.2.1. By Drug Class
        • 16.8.3.2.2. By Indication
        • 16.8.3.2.3. By Pet Type
        • 16.8.3.2.4. By Route of Administration
        • 16.8.3.2.5. By Distribution Channel

17. South Asia Market Analysis 2019-2023 and Forecast 2024-2031

  • 17.1. Introduction / Key Findings
  • 17.2. Historical Market Size (US$ Million) Analysis, By Market Taxonomy, 2019-2023
  • 17.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2024-2031
    • 17.3.1. By Country
      • 17.3.1.1. India
      • 17.3.1.2. Indonesia
      • 17.3.1.3. Thailand
      • 17.3.1.4. Philippines
      • 17.3.1.5. Malaysia
      • 17.3.1.6. Vietnam
      • 17.3.1.7. Rest of South Asia
    • 17.3.2. By Drug Class
    • 17.3.3. By Indication
    • 17.3.4. By Pet Type
    • 17.3.5. By Route of Administration
    • 17.3.6. By Distribution Channel
  • 17.4. Market Attractiveness Analysis By Region
    • 17.4.1. By Country
    • 17.4.2. By Drug Class
    • 17.4.3. By Indication
    • 17.4.4. By Pet Type
    • 17.4.5. By Route of Administration
    • 17.4.6. By Distribution Channel
  • 17.5. Market trends
  • 17.6. Key Market Participants - Intensity Mapping
  • 17.7. Drivers and Restraints - Impact Analysis
  • 17.8. Country Level Analysis & Forecast
    • 17.8.1. India Market Analysis
      • 17.8.1.1. Introduction
      • 17.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.1.2.1. By Drug Class
        • 17.8.1.2.2. By Indication
        • 17.8.1.2.3. By Pet Type
        • 17.8.1.2.4. By Route of Administration
        • 17.8.1.2.5. By Distribution Channel
    • 17.8.2. Indonesia Market Analysis
      • 17.8.2.1. Introduction
      • 17.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.2.2.1. By Drug Class
        • 17.8.2.2.2. By Indication
        • 17.8.2.2.3. By Pet Type
        • 17.8.2.2.4. By Route of Administration
        • 17.8.2.2.5. By Distribution Channel
    • 17.8.3. Thailand Market Analysis
      • 17.8.3.1. Introduction
      • 17.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.3.2.1. By Drug Class
        • 17.8.3.2.2. By Indication
        • 17.8.3.2.3. By Pet Type
        • 17.8.3.2.4. By Route of Administration
        • 17.8.3.2.5. By Distribution Channel
    • 17.8.4. Philippines Market Analysis
      • 17.8.4.1. Introduction
      • 17.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.4.2.1. By Drug Class
        • 17.8.4.2.2. By Indication
        • 17.8.4.2.3. By Pet Type
        • 17.8.4.2.4. By Route of Administration
        • 17.8.4.2.5. By Distribution Channel
    • 17.8.5. Malaysia Market Analysis
      • 17.8.5.1. Introduction
      • 17.8.5.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.5.2.1. By Drug Class
        • 17.8.5.2.2. By Indication
        • 17.8.5.2.3. By Pet Type
        • 17.8.5.2.4. By Route of Administration
        • 17.8.5.2.5. By Distribution Channel
    • 17.8.6. Vietnam Market Analysis
      • 17.8.6.1. Introduction
      • 17.8.6.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.6.2.1. By Drug Class
        • 17.8.6.2.2. By Indication
        • 17.8.6.2.3. By Pet Type
        • 17.8.6.2.4. By Route of Administration
        • 17.8.6.2.5. By Distribution Channel

18. Oceania Market Analysis 2019-2023 and Forecast 2024-2031

  • 18.1. Introduction / Key Findings
  • 18.2. Historical Market Size (US$ Million) Analysis, By Market Taxonomy, 2019-2023
  • 18.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2024-2031
    • 18.3.1. By Country
      • 18.3.1.1. Australia
      • 18.3.1.2. New Zealand
    • 18.3.2. By Drug Class
    • 18.3.3. By Indication
    • 18.3.4. By Pet Type
    • 18.3.5. By Route of Administration
    • 18.3.6. By Distribution Channel
  • 18.4. Market Attractiveness Analysis By Region
    • 18.4.1. By Country
    • 18.4.2. By Drug Class
    • 18.4.3. By Indication
    • 18.4.4. By Pet Type
    • 18.4.5. By Route of Administration
    • 18.4.6. By Distribution Channel
  • 18.5. Market trends
  • 18.6. Key Market Participants - Intensity Mapping
  • 18.7. Drivers and Restraints - Impact Analysis
  • 18.8. Country Level Analysis & Forecast
    • 18.8.1. Australia Market Analysis
      • 18.8.1.1. Introduction
      • 18.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 18.8.1.2.1. By Drug Class
        • 18.8.1.2.2. By Indication
        • 18.8.1.2.3. By Pet Type
        • 18.8.1.2.4. By Route of Administration
        • 18.8.1.2.5. By Distribution Channel
    • 18.8.2. New Zealand Market Analysis
      • 18.8.2.1. Introduction
      • 18.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 18.8.2.2.1. By Drug Class
        • 18.8.2.2.2. By Indication
        • 18.8.2.2.3. By Pet Type
        • 18.8.2.2.4. By Route of Administration
        • 18.8.2.2.5. By Distribution Channel

19. Middle East and Africa Market Analysis 2019-2023 and Forecast 2024-2031

  • 19.1. Introduction / Key Findings
  • 19.2. Historical Market Size (US$ Million) Analysis, By Market Taxonomy, 2019-2023
  • 19.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2024-2031
    • 19.3.1. By Country
      • 19.3.1.1. GCC Countries
      • 19.3.1.2. Turkey
      • 19.3.1.3. Egypt
      • 19.3.1.4. Israel
      • 19.3.1.5. South Africa
      • 19.3.1.6. Northern Africa
      • 19.3.1.7. Rest of Middle East and Africa
    • 19.3.2. By Drug Class
    • 19.3.3. By Indication
    • 19.3.4. By Pet Type
    • 19.3.5. By Route of Administration
    • 19.3.6. By Distribution Channel
  • 19.4. Market Attractiveness Analysis By Region
    • 19.4.1. By Country
    • 19.4.2. By Drug Class
    • 19.4.3. By Indication
    • 19.4.4. By Pet Type
    • 19.4.5. By Route of Administration
    • 19.4.6. By Distribution Channel
  • 19.5. Market trends
  • 19.6. Key Market Participants - Intensity Mapping
  • 19.7. Drivers and Restraints - Impact Analysis
  • 19.8. Country Level Analysis & Forecast
    • 19.8.1. GCC Countries Market Analysis
      • 19.8.1.1. Introduction
      • 19.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 19.8.1.2.1. By Drug Class
        • 19.8.1.2.2. By Indication
        • 19.8.1.2.3. By Pet Type
        • 19.8.1.2.4. By Route of Administration
        • 19.8.1.2.5. By Distribution Channel
    • 19.8.2. Turkey Market Analysis
      • 19.8.2.1. Introduction
      • 19.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 19.8.2.2.1. By Drug Class
        • 19.8.2.2.2. By Indication
        • 19.8.2.2.3. By Pet Type
        • 19.8.2.2.4. By Route of Administration
        • 19.8.2.2.5. By Distribution Channel
    • 19.8.3. Egypt Market Analysis
      • 19.8.3.1. Introduction
      • 19.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 19.8.3.2.1. By Drug Class
        • 19.8.3.2.2. By Indication
        • 19.8.3.2.3. By Pet Type
        • 19.8.3.2.4. By Route of Administration
        • 19.8.3.2.5. By Distribution Channel
    • 19.8.4. Israel Market Analysis
      • 19.8.4.1. Introduction
      • 19.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 19.8.4.2.1. By Drug Class
        • 19.8.4.2.2. By Indication
        • 19.8.4.2.3. By Pet Type
        • 19.8.4.2.4. By Route of Administration
        • 19.8.4.2.5. By Distribution Channel
    • 19.8.5. South Africa Market Analysis
      • 19.8.5.1. Introduction
      • 19.8.5.2. Market Analysis and Forecast by Market Taxonomy
        • 19.8.5.2.1. By Drug Class
        • 19.8.5.2.2. By Indication
        • 19.8.5.2.3. By Pet Type
        • 19.8.5.2.4. By Route of Administration
        • 19.8.5.2.5. By Distribution Channel
    • 19.8.6. Northern Africa Market Analysis
      • 19.8.6.1. Introduction
      • 19.8.6.2. Market Analysis and Forecast by Market Taxonomy
        • 19.8.6.2.1. By Drug Class
        • 19.8.6.2.2. By Indication
        • 19.8.6.2.3. By Pet Type
        • 19.8.6.2.4. By Route of Administration
        • 19.8.6.2.5. By Distribution Channel

20. Market Structure Analysis

  • 20.1. Market Analysis by Tier of Companies
  • 20.2. Market Share Analysis of Top Players (%)
  • 20.3. Market Presence Analysis
    • 20.3.1. Regional Footprint of Players
    • 20.3.2. Product Footprint of Players
    • 20.3.3. Channel Footprint of Players

21. Competition Analysis

  • 21.1. Competition Dashboard
  • 21.2. Key Development Analysis
  • 21.3. Branding and Promotional Strategies, By Key Players
  • 21.4. Competition Deep Dive
    • 21.4.1. Zoetis Animal Healthcare
      • 21.4.1.1. Overview
      • 21.4.1.2. Product Portfolio
      • 21.4.1.3. Key Financials
      • 21.4.1.4. Sales Footprint
      • 21.4.1.5. SWOT Analysis
      • 21.4.1.6. Strategy Overview
        • 21.4.1.6.1. Marketing Strategies
        • 21.4.1.6.2. Channel Strategies
        • 21.4.1.6.3. Product Strategies
    • 21.4.2. Merck and Co.Inc. (US)
      • 21.4.2.1. Overview
      • 21.4.2.2. Product Portfolio
      • 21.4.2.3. Key Financials
      • 21.4.2.4. Sales Footprint
      • 21.4.2.5. SWOT Analysis
      • 21.4.2.6. Strategy Overview
        • 21.4.2.6.1. Marketing Strategies
        • 21.4.2.6.2. Channel Strategies
        • 21.4.2.6.3. Product Strategies
    • 21.4.3. Boehringer Ingelheim GmbH
      • 21.4.3.1. Overview
      • 21.4.3.2. Product Portfolio
      • 21.4.3.3. Key Financials
      • 21.4.3.4. Sales Footprint
      • 21.4.3.5. SWOT Analysis
      • 21.4.3.6. Strategy Overview
        • 21.4.3.6.1. Marketing Strategies
        • 21.4.3.6.2. Channel Strategies
        • 21.4.3.6.3. Product Strategies
    • 21.4.4. Elanco Animal Health Incorporated
      • 21.4.4.1. Overview
      • 21.4.4.2. Product Portfolio
      • 21.4.4.3. Key Financials
      • 21.4.4.4. Sales Footprint
      • 21.4.4.5. SWOT Analysis
      • 21.4.4.6. Strategy Overview
        • 21.4.4.6.1. Marketing Strategies
        • 21.4.4.6.2. Channel Strategies
        • 21.4.4.6.3. Product Strategies
    • 21.4.5. Bayer AG
      • 21.4.5.1. Overview
      • 21.4.5.2. Product Portfolio
      • 21.4.5.3. Key Financials
      • 21.4.5.4. Sales Footprint
      • 21.4.5.5. SWOT Analysis
      • 21.4.5.6. Strategy Overview
        • 21.4.5.6.1. Marketing Strategies
        • 21.4.5.6.2. Channel Strategies
        • 21.4.5.6.3. Product Strategies
    • 21.4.6. Vetoquinol S.A.
      • 21.4.6.1. Overview
      • 21.4.6.2. Product Portfolio
      • 21.4.6.3. Key Financials
      • 21.4.6.4. Sales Footprint
      • 21.4.6.5. SWOT Analysis
      • 21.4.6.6. Strategy Overview
        • 21.4.6.6.1. Marketing Strategies
        • 21.4.6.6.2. Channel Strategies
        • 21.4.6.6.3. Product Strategies
    • 21.4.7. Dechra Pharmaceuticals PLC
      • 21.4.7.1. Overview
      • 21.4.7.2. Product Portfolio
      • 21.4.7.3. Key Financials
      • 21.4.7.4. Sales Footprint
      • 21.4.7.5. SWOT Analysis
      • 21.4.7.6. Strategy Overview
        • 21.4.7.6.1. Marketing Strategies
        • 21.4.7.6.2. Channel Strategies
        • 21.4.7.6.3. Product Strategies
    • 21.4.8. Virbac SA
      • 21.4.8.1. Overview
      • 21.4.8.2. Product Portfolio
      • 21.4.8.3. Key Financials
      • 21.4.8.4. Sales Footprint
      • 21.4.8.5. SWOT Analysis
      • 21.4.8.6. Strategy Overview
        • 21.4.8.6.1. Marketing Strategies
        • 21.4.8.6.2. Channel Strategies
        • 21.4.8.6.3. Product Strategies
    • 21.4.9. IDEXX Laboratories, Inc.
      • 21.4.9.1. Overview
      • 21.4.9.2. Product Portfolio
      • 21.4.9.3. Key Financials
      • 21.4.9.4. Sales Footprint
      • 21.4.9.5. SWOT Analysis
      • 21.4.9.6. Strategy Overview
        • 21.4.9.6.1. Marketing Strategies
        • 21.4.9.6.2. Channel Strategies
        • 21.4.9.6.3. Product Strategies
    • 21.4.10. Ceva Sante Animale
      • 21.4.10.1. Overview
      • 21.4.10.2. Product Portfolio
      • 21.4.10.3. Key Financials
      • 21.4.10.4. Sales Footprint
      • 21.4.10.5. SWOT Analysis
      • 21.4.10.6. Strategy Overview
        • 21.4.10.6.1. Marketing Strategies
        • 21.4.10.6.2. Channel Strategies
        • 21.4.10.6.3. Product Strategies
    • 21.4.11. Kindred Biosciences, Inc.
      • 21.4.11.1. Overview
      • 21.4.11.2. Product Portfolio
      • 21.4.11.3. Key Financials
      • 21.4.11.4. Sales Footprint
      • 21.4.11.5. SWOT Analysis
      • 21.4.11.6. Strategy Overview
        • 21.4.11.6.1. Marketing Strategies
        • 21.4.11.6.2. Channel Strategies
        • 21.4.11.6.3. Product Strategies
    • 21.4.12. Phirbo Animal Health
      • 21.4.12.1. Overview
      • 21.4.12.2. Product Portfolio
      • 21.4.12.3. Key Financials
      • 21.4.12.4. Sales Footprint
      • 21.4.12.5. SWOT Analysis
      • 21.4.12.6. Strategy Overview
        • 21.4.12.6.1. Marketing Strategies
        • 21.4.12.6.2. Channel Strategies
        • 21.4.12.6.3. Product Strategies
    • 21.4.13. Norbrook Laboratories Limited
      • 21.4.13.1. Overview
      • 21.4.13.2. Product Portfolio
      • 21.4.13.3. Key Financials
      • 21.4.13.4. Sales Footprint
      • 21.4.13.5. SWOT Analysis
      • 21.4.13.6. Strategy Overview
        • 21.4.13.6.1. Marketing Strategies
        • 21.4.13.6.2. Channel Strategies
        • 21.4.13.6.3. Product Strategies
    • 21.4.14. Vetiquinol SA
      • 21.4.14.1. Overview
      • 21.4.14.2. Product Portfolio
      • 21.4.14.3. Key Financials
      • 21.4.14.4. Sales Footprint
      • 21.4.14.5. SWOT Analysis
      • 21.4.14.6. Strategy Overview
        • 21.4.14.6.1. Marketing Strategies
        • 21.4.14.6.2. Channel Strategies
        • 21.4.14.6.3. Product Strategies
    • 21.4.15. Neogen Corporation
      • 21.4.15.1. Overview
      • 21.4.15.2. Product Portfolio
      • 21.4.15.3. Key Financials
      • 21.4.15.4. Sales Footprint
      • 21.4.15.5. SWOT Analysis
      • 21.4.15.6. Strategy Overview
        • 21.4.15.6.1. Marketing Strategies
        • 21.4.15.6.2. Channel Strategies
        • 21.4.15.6.3. Product Strategies
    • 21.4.16. PetIQ, Inc.
      • 21.4.16.1. Overview
      • 21.4.16.2. Product Portfolio
      • 21.4.16.3. Key Financials
      • 21.4.16.4. Sales Footprint
      • 21.4.16.5. SWOT Analysis
      • 21.4.16.6. Strategy Overview
        • 21.4.16.6.1. Marketing Strategies
        • 21.4.16.6.2. Channel Strategies
        • 21.4.16.6.3. Product Strategies
    • 21.4.17. Huvepharma AD
      • 21.4.17.1. Overview
      • 21.4.17.2. Product Portfolio
      • 21.4.17.3. Key Financials
      • 21.4.17.4. Sales Footprint
      • 21.4.17.5. SWOT Analysis
      • 21.4.17.6. Strategy Overview
        • 21.4.17.6.1. Marketing Strategies
        • 21.4.17.6.2. Channel Strategies
        • 21.4.17.6.3. Product Strategies
    • 21.4.18. Chanelle Pharma Group Limited
      • 21.4.18.1. Overview
      • 21.4.18.2. Product Portfolio
      • 21.4.18.3. Key Financials
      • 21.4.18.4. Sales Footprint
      • 21.4.18.5. SWOT Analysis
      • 21.4.18.6. Strategy Overview
        • 21.4.18.6.1. Marketing Strategies
        • 21.4.18.6.2. Channel Strategies
        • 21.4.18.6.3. Product Strategies
    • 21.4.19. Kepro
      • 21.4.19.1. Overview
      • 21.4.19.2. Product Portfolio
      • 21.4.19.3. Key Financials
      • 21.4.19.4. Sales Footprint
      • 21.4.19.5. SWOT Analysis
      • 21.4.19.6. Strategy Overview
        • 21.4.19.6.1. Marketing Strategies
        • 21.4.19.6.2. Channel Strategies
        • 21.4.19.6.3. Product Strategies
    • 21.4.20. Biogenesis Bago
      • 21.4.20.1. Overview
      • 21.4.20.2. Product Portfolio
      • 21.4.20.3. Key Financials
      • 21.4.20.4. Sales Footprint
      • 21.4.20.5. SWOT Analysis
      • 21.4.20.6. Strategy Overview
        • 21.4.20.6.1. Marketing Strategies
        • 21.4.20.6.2. Channel Strategies
        • 21.4.20.6.3. Product Strategies

22. Assumptions and Acronyms Used

23. Research Methodology